Status: Not yet recruiting
RELIEVE Study: NT 201 Intravesical Administration Using Vibe System (ViXe Combination Product) for the Treatment of Idiopathic Overactive Bladder
This Phase 2b study is a prospective, multicenter, double blind, randomized, placebo and sham controlled trial to assess the safety, efficacy and dose response of NT 201 delivered by the Vibe System in participants with idiopathic overactive bladder (OAB).
Participants needed: 210
Trial details
Phase: Phase 2Age: 18-80Biological sex: FemaleType: InterventionalSponsor: Vensica Therapeutics Ltd.Updated: Apr 27, 2026
Eligibility criteria
Signed written informed consent [+6]
Participant with Body Mass Index > 40 kg/m2 [+10]